PMID- 32115392
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20211204
IS  - 1544-3450 (Electronic)
IS  - 1544-3191 (Print)
IS  - 1086-5802 (Linking)
VI  - 60
IP  - 5
DP  - 2020 Sep-Oct
TI  - Clinical pharmacists in diabetes management: What do minority patients with 
      uncontrolled diabetes have to say?
PG  - 708-715
LID - S1544-3191(20)30037-6 [pii]
LID - 10.1016/j.japh.2020.01.024 [doi]
AB  - OBJECTIVE: Clinical pharmacist support for patients with type 2 diabetes mellitus 
      (T2DM) can optimize patient outcomes and medication adherence. However, there is 
      limited understanding of what pharmacist roles patients perceive as most helpful 
      in T2DM management interventions. This study describes experiences of minority 
      patients with uncontrolled T2DM in terms of perceived pharmacist helpfulness and 
      specific roles found to be most helpful within diabetes management. DESIGN: A 
      secondary analysis of a 2-year randomized, crossover trial was conducted. SETTING 
      AND PARTICIPANTS: This study included 244 African American and Hispanic adults 
      with uncontrolled T2DM who received clinical pharmacist support within a 
      team-based model. OUTCOME MEASURES: The patients completed a mixed-methods survey 
      regarding their experience with the intervention that included a general 
      helpfulness rating on a 10-point unipolar Likert scale and described the support 
      qualitatively, including their perception of the pharmacist roles. Thematic 
      analysis guided coding of the responses. RESULTS: One hundred forty-seven (60%) 
      patients completed the survey and had at least 1 encounter with a clinical 
      pharmacist. Of these, 108 (74%) were African American, 39 (27%) were Hispanic, 
      and 101 (69%) were women. The median rating of clinical pharmacist helpfulness 
      was 10 (very helpful). Only 10 (7%) participants rated pharmacist helpfulness as 
      1 (not at all helpful). "Medication education and management" was the most 
      frequently perceived supportive role of the clinical pharmacists, followed by 
      "non-medication-related patient education," "social support," and "care 
      coordination." Miscommunication related to scheduling was the most common reason 
      cited for not meeting with the clinical pharmacist. CONCLUSION: This sample of 
      minority patients with uncontrolled T2DM recognized many roles outlined within 
      the American Pharmacists Association Medication Therapy Management framework. 
      Patient experiences with clinical pharmacist T2DM support are crucial for 
      developing effective programs, maximizing patient engagement, satisfying patient 
      needs, and ensuring that a program's intended purpose aligns with the patient 
      perspective.
CI  - Copyright (c) 2020 American Pharmacists Association(R). Published by Elsevier Inc. 
      All rights reserved.
FAU - Nabulsi, Nadia A
AU  - Nabulsi NA
FAU - Yan, Connie H
AU  - Yan CH
FAU - Tilton, Jessica J
AU  - Tilton JJ
FAU - Gerber, Ben S
AU  - Gerber BS
FAU - Sharp, Lisa K
AU  - Sharp LK
LA  - eng
SI  - ClinicalTrials.gov/NCT01498159
GR  - R01 DK091347/DK/NIDDK NIH HHS/United States
GR  - UL1 TR002003/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20200227
PL  - United States
TA  - J Am Pharm Assoc (2003)
JT  - Journal of the American Pharmacists Association : JAPhA
JID - 101176252
SB  - IM
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Female
MH  - Hispanic or Latino
MH  - Humans
MH  - Medication Adherence
MH  - Medication Therapy Management
MH  - *Pharmacists
PMC - PMC7483142
MID - NIHMS1569024
COIS- CONFLICT OF INTEREST STATEMENT The authors declare that there is no conflict of 
      interest regarding the publication of this article.
EDAT- 2020/03/03 06:00
MHDA- 2021/06/29 06:00
PMCR- 2021/09/01
CRDT- 2020/03/03 06:00
PHST- 2019/11/25 00:00 [received]
PHST- 2020/01/21 00:00 [revised]
PHST- 2020/01/26 00:00 [accepted]
PHST- 2020/03/03 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/03/03 06:00 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - S1544-3191(20)30037-6 [pii]
AID - 10.1016/j.japh.2020.01.024 [doi]
PST - ppublish
SO  - J Am Pharm Assoc (2003). 2020 Sep-Oct;60(5):708-715. doi: 
      10.1016/j.japh.2020.01.024. Epub 2020 Feb 27.